Clinical Trials
Below are current clinical trials.
196 studies in Pulmonary and Critical Care Medicine Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn., Jacksonville, Fla.
In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter Syndrome (rrRS) will receive pembrolizumab (MK-3475). The efficacy of pembrolizumab in the treatment of rrPMBCL and rrRS will be evaluated.
-
Jacksonville, Fla.
The purpose of this study is to describe in detail the smoking history in a population of acute or prior cerebrovasculqar accident (CVA) patients and identify those who qualify for lung cancer screening by criteria outlined by three separate organizations.
-
Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.
This trial will evaluate the safety and effectiveness of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant phase] in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).
-
La Crosse, Wis., Mankato, Minn., Jacksonville, Fla., Rochester, Minn., Eau Claire, Wis.
The purpose of this study is to evaluate the safety and effectiveness of Ravulizumab compared to Supportive Care in patients with COVID-19 severe pneumonia.
-
Rochester, Minn.
The purpose of this study is to provide the lung volume reduction coil treatment procedure to patients who were randomized to the control group in study CLN0009, and obtain safety and effectiveness data on these patients.
-
Rochester, Minn.
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid "Master Protocol" (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a "non-match" sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
-
Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.
The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).
-
Rochester, Minn.
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat alone or with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).
-
Rochester, Minn.
This study is being done to evaluate the immune system in patients with lung cancer or mesothelioma. We are going to analyze which genes are expressed by cells that fight infections to see if there are any relations to cancer.
-
Rochester, Minn.
The purpose of this pilot study is to see if recruitment maneuvers performed during ICU care in patients who have a breathing tube are useful in assessing a blood volume status based on changes in their blood pressure during the recruitment maneuver. The recruitment maneuver consists of increasing the pressure of the breath given through the breathing tube, and is commonly done as a standard part of ICU care for patients who are connected to a machine that helps them breathe. Results will be compared to ultrasound measurements of the main vein of the body (inferior vena cava) which serve as a non-invasive standard of care technique.